Psylo
Signal active
Organization
Contact Information
Overview
Psylo is a drug development company that focuses on next-generation psychedelics. With psychedelic molecules as the starting point, our goal is to develop medicines that are widely available as improved treatments to currently available SSRI medications.
About
Industries
Biotechnology
Founded
2021
Employees
11-50
Headquarters locations
Sydney, New South Wales, Australia, Oceania
Social
N/A
Profile Resume
Psylo headquartered in Sydney, New South Wales, Australia, Oceania, operates in the Biotechnology sector. The company focuses on Biotechnology and has secured $144.3M in funding across 12 round(s). With a team of 11-50 employees, Psylo is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Psylo, raised $8.0M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
3
Investors
7
Lead Investors
0
Total Funding Amount
$12.0M
Details
3
Psylo has raised a total of $12.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2022 | Seed | 3.2M | ||
| 2021 | Seed | 798.9K | ||
| 2024 | Seed | 8.0M |
Investors
Psylo is funded by 23 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Emily Rich | - | FUNDING ROUND - Emily Rich | 8.0M |
| Alan Jones | - | FUNDING ROUND - Alan Jones | 8.0M |
| Psylo | - | FUNDING ROUND - Psylo | 8.0M |
| M8 Ventures | - | FUNDING ROUND - M8 Ventures | 8.0M |
Recent Activity
There is no recent news or activity for this profile.